The Prospect of Using Serum Taurine Level as a Potential Biomarker for Early Detection of Colorectal Carcinoma and Its Correlation With Other Prognostic Markers

Not Applicable

Completed

• Conditions: Taurine in Cancer Colon
• Interventions: Diagnostic Test: Taurine

• Registration Number: NCT04192539
• Lead Sponsor: Ain Shams University

Brief Summary

Serum taurine results in this study showed that, besides CRC biomarkers; it is most attractive, more precious and more accurate early biomarker for early detecting of any malignant change which may led to CRC by other mean it is the most sensitive and more specific tumor marker for CRC. As a result, we can recommend measuring its level regularly with other prognostic tumor biomarkers and screening examination for all people with abdominal and gastrointestinal problems and for precancerous patients as a pre-early biomarker for colorectal carcinoma. So, it needs further studies to confirm that observations on large scale of population as it obvious the small sample size in early stage and lack data due to limited financial resources and it needs more efforts to collect first and precancerous stages patients.

Detailed Description

Two-hundred and fifty Egyptian patients (males and females) who attended National Cancer Institute, Cairo university; most of them were referred from private clinics and non-specialized hospitals, complain with abdominal troubles and gastrointestinal problems and bleeding per rectum, after full investigation, clinical examination, biochemical analysis, screening examination according to their cases (Ultra sound, CT or endoscopy either rectal or colonoscopy) and histopathological examination, we choose 'after their approval' one-hundred patients and six which diagnosed as CRC patients aged (19-69 years old) and excluded the others from participated in these studies because they diagnosed as non-colonic diseases like; Irritable colon, Gastroenteritis, Pancreatitis, Liver flexure or Chronic cholecystitis. According to Histopathological architecture, we divided patients to:

1. Inflammatory group number=7.

2. Benign tumor group number=8 which was assessed preoperatively and postoperatively.

3. Malignant tumor group number=91 Lastly, ten health volunteers were enrolled as a frank control. For all included subjects, the measured biochemical analysis were CBC, ALT, AST, Albumin, Total Bilirubin, Creatinine, Blood urea, Sodium, Potassium, CEA, CA19.9 and Taurine.

Study Timeline

• Study Start: 2017-01-18
• Primary Completion: 2018-02-20
• Study Completion: 2018-12-17
• Status Verified: 2019-12
• Study First Submitted: 2019-12-07
• Study First Submitted QC: 2019-12-07
• Last Update Submitted: 2019-12-09
• Study First Posted: 2019-12-10
• Last Update Posted: 2019-12-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 116

Inclusion Criteria

Patients complain of abdominal troubles and gastrointestinal problems and bleeding per rectum

Read More

Exclusion Criteria

Patients refusal,non-colonic diseases like; Irritable colon, Gastroenteritis, Pancreatitis, Chronic cholecystitis

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control	Taurine	-
Benign group	Taurine	-
Inflammation	Taurine	-
Malignant group	Taurine	-

Primary Outcome Measures

Name	Time	Method
serum taurine levels	8 months

Trial Locations

Locations (1)

Hanaa El Gendy; 🇪🇬 Cairo, Ain Shams University Specialized Hospital, Egypt